Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type

Type

Guidance programme 1 selected

Guidance programme

Showing 1 to 50 of 881

TitleReference numberPublishedLast updated
12 SQ-HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dust mitesTA1045
Abaloparatide for treating osteoporosis after menopauseTA991
Abatacept for treating psoriatic arthritis after DMARDs (terminated appraisal)TA568
Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritisTA373
Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancerTA563
Abemaciclib with endocrine therapy for adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrenceTA810
Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapyTA725
Abiraterone (originator and generics) for treating newly diagnosed high-risk hormone‑sensitive metastatic prostate cancerTA1110
Abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimenTA259
Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicatedTA387
Abrocitinib, tralokinumab or upadacitinib for treating moderate to severe atopic dermatitisTA814
Acalabrutinib for treating chronic lymphocytic leukaemiaTA689
Acoramidis for treating transthyretin amyloidosis with cardiomyopathyTA1121
Adagrasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer (terminated appraisal)TA1076
Adalimumab and dexamethasone for treating non-infectious uveitisTA460
Adalimumab for treating moderate to severe hidradenitis suppurativaTA392
Adalimumab for treating moderate to severe plaque psoriasisTA146
Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young peopleTA455
Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failedTA715
Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failedTA375
Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitorTA195
Adefovir dipivoxil and peginterferon alfa-2a for the treatment of chronic hepatitis BTA96
Afatinib for treating advanced squamous non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal)TA444
Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancerTA310
Aflibercept for treating choroidal neovascularisationTA486
Aflibercept for treating diabetic macular oedemaTA346
Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusionTA409
Aflibercept for treating visual impairment caused by macular oedema secondary to central retinal vein occlusionTA305
Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapyTA307
Aflibercept solution for injection for treating wet age‑related macular degenerationTA294
Agomelatine for the treatment of major depressive episodes (terminated appraisal)TA231
Alectinib for adjuvant treatment of ALK-positive non-small-cell lung cancerTA1014
Alectinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (terminated appraisal)TA438
Alectinib for untreated ALK-positive advanced non-small-cell lung cancerTA536
Alemtuzumab for treating highly active relapsing–remitting multiple sclerosisTA312
Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemiaTA393
Alitretinoin for the treatment of severe chronic hand eczemaTA177
Alpelisib with fulvestrant for treating hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancerTA816
Alteplase for treating acute ischaemic strokeTA264
Amantadine, oseltamivir and zanamivir for the treatment of influenzaTA168
Amivantamab for treating EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapyTA850
Amivantamab with lazertinib for untreated EGFR mutation-positive advanced non-small-cell lung cancerTA1122
Anakinra for treating Still's diseaseTA685
Andexanet alfa for reversing anticoagulation from apixaban or rivaroxabanTA697
Andexanet alfa for reversing anticoagulation in people with intracranial haemorrhage (terminated appraisal)TA1029
Angiotensin II for treating vasosuppressor-resistant hypotension caused by septic or distributive shock (terminated appraisal)TA859
Anhydrous sodium thiosulfate for preventing hearing loss caused by cisplatin chemotherapy in people 1 month to 17 years with localised solid tumoursTA1034
Anifrolumab for treating active autoantibody-positive systemic lupus erythematosus (terminated appraisal)TA793
Apalutamide with androgen deprivation therapy for treating high-risk hormone-relapsed non-metastatic prostate cancerTA740
Apalutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancerTA741

Results per page

  1. 10
  2. 25
  3. 50
  4. All